Akero Therapeutics

San Francisco, United States Founded: 2017 • Age: 9 yrs Listed Acquired By Novo Nordisk
Small molecule therapeutics for metabolic disorders are developed.

About Akero Therapeutics

Akero Therapeutics is a publicly listed company based in San Francisco (United States) founded in 2017, and was acquired by Novo Nordisk in October 2025. Small molecule therapeutics for metabolic disorders are developed. Akero Therapeutics has raised $135 million across 4 funding rounds from investors including Pfizer, Novo Nordisk and Janus Henderson Investors. The company has 63 employees. Its website akerotx.com draws about 12 thousand monthly visits. Akero Therapeutics offers products and services including Efruxifermin (EFX). Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its legal entity is AKERO THERAPEUTICS, INC. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.

Company details

Akero Therapeutics was founded in 2017 and is headquartered in San Francisco, United States. Small molecule therapeutics targeting metabolic disorders, including non-alcoholic steatohepatitis, fibrosis, and liver diseases, are developed by the company. The lead product, Efruxifermin, functions as an agonist of fibroblast growth factor 21. Operations focus on advancing these treatments within the biotechnology sector.

  • Headquarters San Francisco, United States
  • Employees 63
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website akerotx.com
  • Social LinkedIn X
  • Acquired by Novo Nordisk (Oct 2025)
  • Legal Name Akero Therapeutics, Inc.
Operational Areas
Key Metrics
  • Net Profit
    -$252.06 M (USD)
    -66.09
    as on Dec 31, 2024
  • EBITDA
    -$285.4 M (USD)
    -65.13
    as on Dec 31, 2024
  • Total Equity Funding
    $135M (USD)

    in 4 rounds

  • Latest Funding Round
    $25M (USD), Post-IPO

    Jun 2022

  • Investors
    Pfizer

    & 11 more

  • Employee Count
    63
  • Acquired by
    Novo Nordisk

    (Oct 2025)

Products & Services of Akero Therapeutics

Akero Therapeutics offers a comprehensive portfolio of products and services, including Efruxifermin (EFX).

Efruxifermin (EFX)
Therapeutic Drug

Investigational treatment for metabolic dysfunction-associated steatohepatitis.

Funding Insights of Akero Therapeutics

Akero Therapeutics has successfully raised a total of $135M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $135M
  • Total Rounds 4
  • Last Round Post-IPO β€” $25M
  • First Round $65M

    (Jun 2018)

  • Investors Count 11

All 4 funding rounds of Akero Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2022$25MPost-IPO––
Jul 2020$216.44MPost-IPO––
–
Dec 2018$70MSeries B–Janus Henderson Investors
Jun 2018$65MSeries A–Apple Tree Partners, Atlas Venture
Valuation history

12 investors in total: 12 institutional.

Investors in Akero Therapeutics

Akero Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Novo Nordisk and Janus Henderson Investors.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Healthcare startups are funded by this corporate-backed venture capital entity.
lifesciventure.comNew York, United States
Multiple sectors are targeted for venture capital investments.
1934janushenderson.comLondon, United Kingdom
Apple Tree Partners is engaged in life sciences venture capital.
appletreepartners.com
Venture capital firm investing in life science and biotechnology sectors
1980atlasventure.comCambridge, United States
US private equity investments are managed by BVF Partners.
bvflp.comSan Francisco, United States
Early-stage and late-stage biotech and finance companies are funded.
rockspringscapital.comBaltimore, United States
A life sciences investment firm focused on novel therapeutics is operated.
2011venbio.comSan Francisco, United States
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
versantventures.com
Biotech startups are funded by this venture capital firm.
boxercap.comSan Diego, United States
Pharmaceutical products for treating multiple diseases are provided.
1849pfizer.comNew York, United States
Premium access

Investor details for Akero Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Akero Therapeutics

53 people are tracked at Akero Therapeutics (30 in leadership, 7 in board & advisors, 16 in team); the tracked headcount is 63.

NameRoleGroup
Erik Tillman
Director, Translational Biology & PharmacologyLeadership
Catriona Yale
Chief Development OfficerLeadership
Jonathan Young
COO & Co FounderLeadership
William White
CFO & Head of Corporate DevelopmentLeadership
Tim Rolph
Chief Scientific Officer & Co-FounderLeadership
Scott Gangloff
Chief Technical OfficerLeadership
Reshma Shringarpure
VP, Clinical Research & Medical AffairsLeadership
Andrew Cheng
President & CEOLeadership
Arin Bose
VP for Drug Substance Process DevelopmentLeadership
Sean Doyle
Vice President OperationsLeadership
Lucy N.
Sr Director, Fp&aLeadership
John Schembri
VP, Finance & ControllerLeadership
Brittany de Temple
VP of Development OperationsLeadership
Libette Luce
VP of Regulatory AffairsLeadership
Thomas Quinn
Senior Director, ControllerLeadership
Lina Patel
Director, Quality ControlLeadership
Mark Burch
Director BiostatisticsLeadership
Doreen Chan
Associate Director, Clinical ResearchLeadership
Yasmine Rafidi
Vp, Fp&aLeadership
Kimberly Barrett
Director, Clinical Data ManagementLeadership

33 more people are available in the full profile.

Premium access

Complete people profiles for Akero Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Akero Therapeutics

Akero Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AKRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Jun 2019
  • Listed onNASDAQ: AKRO
  • Listed entityAkero Therapeutics, Inc.
  • Exchange sectorHealth technology
  • ISINUS00973Y1082
  • Share price$54.65 (+0.18% on the day) · 2025-12-10
  • Market capitalisation$4.50B
  • EPS (diluted, trailing year)$-3.75
  • Volume (last session)15,312,254
  • Analyst consensusNeutral

Financials of Akero Therapeutics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2024-$252.1M-$285.4M
2023-$151.8M-$172.8M
2022-$112.0M-$114.9M
2021-$100.8M-$100.6M
2020-$79.2M-$79.9M
Premium access

Detailed financial statements for Akero Therapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Akero Therapeutics

5 dated milestones of Akero Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Akero Therapeutics is founded.
  2. Funding First funding round of $65.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $25.0M.
  5. Exit Acquired by Novo Nordisk.

Competitors of Akero Therapeutics

Akero Therapeutics has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
ngmbio.com2007San Francisco, United States$358.87M225
Biologics are developed for cardio-metabolic and liver diseases.
nimbustx.com2009Cambridge, United States$685M81
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
altimmune.com1997Gaithersburg, United States$58M17
Vaccines for infectious diseases and solid tumors are developed.
Premium access

Detailed competitors of Akero Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Akero Therapeutics

The website of Akero Therapeutics (akerotx.com) receives about 12.4K visits a month and ranks #1,579,833 among all websites worldwide, #2,116 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    12.4K

    ▼ 27.7% vs previous month

  • Unique visitors
    7.4K

    per month

  • Global rank
    #1,579,833

    among all websites

  • Category rank
    #2,116

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Akero Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
biopharmadive.com
100%
680.7K#208,628View details

Top companies in Metabolic Diseases

3 companies that operate in the same segment as Akero Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
2010Boston, Massachusetts, United StatesUSD 84 MUSD 189.76 M283
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Akero Therapeutics

Premium access

Complete news archive for Akero Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Akero Therapeutics

Akero Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Akero Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Akero Therapeutics is a funded company, having raised a total of $135M across 4 funding rounds to date. The company's 1st funding round was a Series A of $65M, raised on Jun 2018.

Akero Therapeutics has 63 employees.

Akero Therapeutics was founded in 2017 and is headquartered in San Francisco, United States. Small molecule therapeutics targeting metabolic disorders, including non-alcoholic steatohepatitis, fibrosis, and liver diseases, are developed by the company. The lead product, Efruxifermin, functions as an agonist of fibroblast growth factor 21. Operations focus on advancing these treatments within the biotechnology sector.

Akero Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.

Akero Therapeutics offers Efruxifermin (EFX).

Yes, Akero Therapeutics is publicly traded on NASDAQ under the ticker symbol AKRO.

Akero Therapeutics has 12 investors. Key investors include Pfizer, Novo Nordisk, Janus Henderson Investors, Atlas Venture, and LifeSci Venture Partners.

Akero Therapeutics operates through Akero Therapeutics, Inc..

Yes. Akero Therapeutics was acquired by Novo Nordisk in October 2025.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available